GlassScriptPhysician profile
Nathan Cash
NPI 1013644277
$1,953.00
in general payments reported to CMS, 2019-2025
12 companies · $810 in 2025
The $810 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $81.22 · 2023: $628 · 2024: $433 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $549.54 | 2023-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $454.24 | 2023-2025 | Infuse, Vyzulta, Miebo |
| Alcon Vision LLC | $279.87 | 2023-2025 | Tryptyr, Precision 1, Total30 |
| Tarsus Pharmaceuticals, INC. | $188.05 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $114.63 | 2022-2025 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $109.98 | 2023 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $92.37 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $45.41 | 2023-2024 | Cequa |
| Abbvie INC. | $44.96 | 2022 | |
| Glaukos Corporation | $28.08 | 2025 | Photrexa Viscous and Photrexa |
| Biotissue Holdings INC. | $25.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Cash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.